Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Levocetirizine
Drug ID BADD_D01272
Description Levocetirizine is a selective histamine H1 antagonist used to treat a variety of allergic symptoms.[A181748,A181790,L7694] It is the R enantiomer of [cetirizine].[L7694] Levocetirizine has greater affinity for the histamine H1 receptor than cetirizine.[L7694] Levocetirizine was granted FDA approval in 1995.[L7694]
Indications and Usage Levocetirizine is indicated for the relief of symptoms associated with allergic rhinitis (seasonal and perennial) in adults and children 6 years of age and older.
Marketing Status Prescription; OTC; Discontinued
ATC Code R06AE09
DrugBank ID DB06282
KEGG ID D07402
MeSH ID C472067
PubChem ID 1549000
TTD Drug ID D0M8PW
NDC Product Code Not Available
Synonyms levocetirizine | levocetrizine | acetic acid, (2-(4-((R)-(4-chlorophenyl)phenylmethyl)-1-piperazinyl)ethoxy)- | (2-(4-((R)-p-chloro-alpha-phenylbenzyl)-1-piperazinyl)ethoxy)acetic acid | levocetirizine hydrochloride | Xusal | levocetirizine dihydrochloride | (2-(4-((R)-(4-chlorophenyl)phenylmethyl)piperazin-1-yl)ethoxy)acetic acid dihydrochloride | cetirizine (R)-form dihydrochloride | acetic acid, (2-(4-((R)-(4-chlorophenyl)phenylmethyl)-1-piperazinyl)ethoxy)-, dihydrochloride | Xyzal | UCB-28556
Chemical Information
Molecular Formula C21H25ClN2O3
CAS Registry Number 130018-77-8
SMILES C1CN(CCN1CCOCC(=O)O)C(C2=CC=CC=C2)C3=CC=C(C=C3)Cl
Chemical Structure
ADR Related Proteins Induced by Drug
ADR Term Protein Name UniProt AC TTD Target ID PMID
Not AvailableNot AvailableNot AvailableNot AvailableNot Available
ADRs Induced by Drug
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Conjunctival hyperaemia06.04.01.0040.000877%Not Available
Urticaria chronic23.04.02.009; 10.01.06.009--Not Available
Pruritus generalised23.03.12.0030.000877%Not Available
Musculoskeletal discomfort15.03.04.001--Not Available
Haemorrhage24.07.01.0020.001169%Not Available
Hypoaesthesia oral17.02.06.021; 07.05.05.0030.000585%Not Available
Toxic skin eruption23.03.05.003; 10.01.01.0080.000585%Not Available
Blood alkaline phosphatase increased13.04.02.0040.000585%
Hepatic enzyme increased13.03.01.0190.000585%Not Available
Eye movement disorder17.02.05.025; 06.05.02.0080.000585%Not Available
Sudden hearing loss04.02.01.0090.000585%Not Available
Decreased appetite14.03.01.005; 08.01.09.028--
Pseudomonas infection11.02.12.0010.000585%Not Available
Psychiatric symptom19.01.02.0010.000585%Not Available
Renal impairment20.01.03.0100.002339%Not Available
Oropharyngeal discomfort22.02.05.027; 07.05.05.0080.000585%Not Available
Oropharyngeal pain22.02.05.022; 07.05.05.0040.000585%
Creatinine renal clearance abnormal13.13.01.0160.000585%Not Available
Drug-induced liver injury09.01.07.023; 12.03.01.0440.005847%Not Available
Mouth swelling10.01.05.020; 07.05.04.007; 23.04.01.0200.000585%Not Available
Alopecia areata23.02.02.008; 10.04.02.0110.001462%Not Available
Blood cholinesterase decreased13.03.01.0270.000585%Not Available
Blood immunoglobulin A increased13.06.05.0090.000585%Not Available
Faeces pale07.01.03.0050.000585%Not Available
Epstein-Barr virus antibody positive13.08.03.0150.000585%Not Available
Sopor19.02.04.002; 17.02.04.0210.000585%Not Available
Nail growth abnormal23.02.05.0240.000585%Not Available
The 7th Page    First    Pre   7    Total 7 Pages